https://doi.org/10.55788/9a26835c
By identifying treatable traits in individual patients, a personalised medicine approach may be developed which can help improve outcomes for the individual patient [1,2]. In patients with uncontrolled or severe asthma, pulmonary treatable traits include blood and sputum eosinophils, FeNO, allergy, fixed airflow limitation, small airway dysfunction, airway infections, as well as extrapulmonary treatable traits such as chronic rhinosinusitis (CRS) with or without nasal polyps, gastroesophageal reflux disease (GERD), obesity, metabolic and cardiovascular disease, and behavioural traits: especially anxiety and depression [3-5]. Dr Schleich showed results from a small study (n=55) with a duration of 16 weeks in which the feasibility and effects of a multidisciplinary treatment plan targeted at predefined treatable traits was compared with usual care in patients with uncontrolled severe asthma. The primary endpoint was the patient-reported outcome of health-related quality of life. Patients presented with on mean 10.44 traits per individual patient (3.01 pulmonary and 4.85 extrapulmonary traits, and 2.58 behavioural/risk factors). Researchers showed that an individualised treatment strategy aimed at treatable traits of individual patients was feasible in a clinical setting and significantly improved health-related quality of life as measured by the Asthma Quality of Life Questionnaire (AQLQ) (0.86 units, P<0.001) and asthma control according to the Asthma Control Questionnaire (ACQ) (0.73, P=0.01). Thus, in patients with uncontrolled asthma, identifying and targeting of treatable traits may offer a clinically useful approach to effectively deal with the complexity of the disease in individual patients [6,7].
- Agusti A, et al. ERJ. 2017;50:1701655.
- McDonald VM, et al. ERJ. 2019;53:1802058.
- Couillard S, et al. Thorax. 2022;77:199–202.
- Dunican EM, et al. J Clin Invest. 2018 Mar 1;128(3):997-1009.
- Gibson PG, et al. Lancet. 2017;390(10095):659-668.
- McDonald VM, et al. ERJ. 2020;55:1901509.
- Schleich F. Asthma. Nordic Lung Congress 2022, 01–03 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Social distancing led to a reduced number of exacerbations in bronchiectasis patients Next Article
Switching biologicals in severe asthma »
« Social distancing led to a reduced number of exacerbations in bronchiectasis patients Next Article
Switching biologicals in severe asthma »
Table of Contents: NLC 2022
Featured articles
Respiratory Disease and Physical Activity
Physical activity improves asthma control
Exercise training for IPF patients is feasible but access needs to be improved
Respiratory Disease and Reproduction
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Palliative Care in Respiratory Diseases
Advance care planning
Biologics in Asthma
Treatable Traits in Obstructive Airway Diseases
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Bronchiectasis
Challenges in Upper Airway Diseases
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
Interstitial Lung Diseases (ILD)
Rheumatoid arthritis-associated ILD
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
Update on treatment of fibrotic ILD
Respiratory Failure
Lung Cancer Screening in the Nordics
Points of interest for radiologists screening for lung cancer
E-cigarettes
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
Vaping amongst adolescents: an alarming trend
Tuberculosis and Sarcoidosis
Detection of latent TB infection key to preventing the spread of the disease
Related Articles
August 17, 2022
New antigens in sarcoidosis
August 17, 2022
Fatigue syndrome in sarcoidosis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com